Mark Massaro is ranked #1401 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Mark Massaro (BTIG) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Mark Massaro's stock ratings?

About 67% of Mark's ratings were profitable over a one-year hold, with an average return of +10.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Mark Massaro

BTIG

Mark Massaro

BTIG

Wall Street Analyst

★★★☆☆

#1401

on 13Foresight · ranked by our own returns

67%

Success Rate

+10.9%

Average Return

22 of 33 calls profitable · +4.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 67% of Mark Massaro's ratings turned a profit when each position was held for 1 year — averaging +10.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

92 Buy 23 Hold 2 Sell

Mark's Stock Coverage 36 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
SOPH SOPHiA GENETICS	Jun 15, 2026	BUY	Strong Buy +75.8% avg upside 7 analysts	$8.00 46.43% Upside	·
TEM Tempus AI, Inc. Class A	Jun 01, 2026	BUY	Strong Buy +33.8% avg upside 19 analysts	$80.00 57.27% Upside	-4.2%
GH Guardant Health	May 27, 2026	BUY	Strong Buy -5.8% avg upside 30 analysts	$160.00 21.33% Upside	+1.2%
LUCD Lucid Diagnostics	May 15, 2026	BUY	Strong Buy +350.9% avg upside 8 analysts	$2.50 131.39% Upside	+3.4%
IMDX Insight Molecular Diagnostics	May 15, 2026	HOLD	Buy -0.6% avg upside 10 analysts	—	·
TKNO Alpha Teknova	May 14, 2026	HOLD	Strong Buy +176.5% avg upside 7 analysts	—	+39.2%
MDXH MDxHealth	May 13, 2026	BUY	Strong Buy +1066.0% avg upside 8 analysts	$4.00 636.67% Upside	-69.9%
CSTL Castle Biosciences	May 13, 2026	BUY	Strong Buy +98.2% avg upside 9 analysts	$40.00 89.48% Upside	+5.4%
MXCT MaxCyte	May 13, 2026	HOLD	Buy +230.6% avg upside 5 analysts	—	+2.0%
XGN Exagen	May 12, 2026	BUY	Strong Buy +161.5% avg upside 10 analysts	$8.00 76.16% Upside	-1.9%
PSNL Personalis	May 11, 2026	BUY	Strong Buy +13.8% avg upside 11 analysts	$11.00 4.35% Upside	+82.3%
BLLN BillionToOne, Inc. Class A	May 07, 2026	BUY	Strong Buy +16.4% avg upside 8 analysts	$130.00 23.53% Upside	+8.8%
CAI Caris Life Sciences, Inc.	May 07, 2026	BUY	Strong Buy +54.5% avg upside 20 analysts	$32.00 73.18% Upside	-16.9%
ADPT Adaptive Biotechnologies	May 06, 2026	BUY	Strong Buy +20.0% avg upside 14 analysts	$22.00 25.58% Upside	+22.0%
WGS GeneDx Holdings	May 05, 2026	BUY	Strong Buy +35.9% avg upside 9 analysts	$90.00 52.43% Upside	+77.7%
CERS Cerus	May 01, 2026	BUY	Strong Buy +99.1% avg upside 10 analysts	$4.00 48.22% Upside	+3.7%
NEO NeoGenomics	Apr 30, 2026	HOLD	Strong Buy +40.2% avg upside 17 analysts	—	+20.4%
CDNA CareDx	Apr 29, 2026	BUY	Buy +26.1% avg upside 16 analysts	$28.00 6.89% Upside	+11.8%
DNA Ginkgo Bioworks Holdings	Mar 12, 2026	SELL	Sell -14.6% avg upside 5 analysts	$5.00 45.48% Downside	-33.6%
NTRA Natera	Mar 03, 2026	BUY	Strong Buy +7.6% avg upside 26 analysts	$260.00 12.35% Upside	+9.4%
ZTS Zoetis	Feb 26, 2026	BUY	Buy +71.4% avg upside 22 analysts	$160.00 103.19% Upside	-40.2%
IDXX Idexx Laboratories	Feb 03, 2026	BUY	Buy +29.2% avg upside 17 analysts	$800.00 42.29% Upside	-11.3%
BNGO BioNano Genomics	Aug 22, 2025	HOLD	Strong Buy +724.8% avg upside 9 analysts	—	-68.5%
RNLXY Renalytix	May 20, 2024	BUY	Strong Buy +800.3% avg upside 5 analysts	$2.00 67.45% Upside	·
HLTHQ Cue Health	Mar 21, 2024	HOLD	Hold 2 analysts	—	-100.0%
TTOO T2 Biosystems	Sep 22, 2023	HOLD	Buy +1473337.5% avg upside 10 analysts	—	·
HTGMQ HTG Molecular Diagnostics	Dec 06, 2019	HOLD	Buy +7333233.3% avg upside 6 analysts	—	·
QDEL QuidelOrtho	Nov 17, 2019	BUY	Buy +185.5% avg upside 13 analysts	$75.00 448.65% Upside	+201.7%
OSUR Orasure Technologies	Nov 10, 2019	HOLD	Buy +99.5% avg upside 11 analysts	$8.00 88.21% Upside	·
QTRX Quanterix	Nov 06, 2019	BUY	Buy +464.7% avg upside 8 analysts	$35.00 932.41% Upside	+157.7%
LH Labcorp Holdings	Oct 24, 2019	HOLD	Strong Buy +1.8% avg upside 36 analysts	$170.00 33.47% Downside	+26.3%
ILMN Illumina	Oct 24, 2019	HOLD	Buy -10.0% avg upside 30 analysts	$310.00 91.38% Upside	+2.5%
DGX Quest Diagnostics	Oct 22, 2019	BUY	Buy -12.4% avg upside 33 analysts	$113.00 42.01% Downside	+28.2%
AWHL Aspira Women's Health	May 23, 2018	HOLD	Strong Buy +990.1% avg upside 6 analysts	$1.00 104.02% Upside	+8.6%
RIOT Riot Platforms	Feb 09, 2016	HOLD	Strong Buy +0.3% avg upside 28 analysts	$4.00 85.75% Downside	+25.7%
BDX Becton Dickinson	May 07, 2015	HOLD	Buy +35.6% avg upside 25 analysts	$145.00 0.80% Upside	+17.5%

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Mark Massaro — Frequently Asked Questions

How accurate are Mark Massaro's stock ratings?

Based on the calls 13Foresight could measure, about 67% of Mark's ratings were profitable over a one-year hold, with an average return of +10.6% per rating, or +3.7% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Mark ranked on 13Foresight?

Mark Massaro is currently ranked #1401 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Mark cover?

Mark most recently has ratings on SOPH, TEM, GH, LUCD, IMDX, TKNO, MDXH, CSTL, MXCT, XGN, PSNL, BLLN and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!